RQ 01
Alternative Names: RQ-001; RQ-01Latest Information Update: 13 Aug 2024
At a glance
- Originator Red Queen Therapeutics
- Class Antivirals; Peptides
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
- Research Common cold; Metapneumovirus infections; Middle East respiratory syndrome coronavirus
Most Recent Events
- 06 Aug 2024 Efficacy and adverse event data from the phase I trial in COVID-2019 infections released by Red Queen Therapeutics
- 03 Jan 2024 Red Queen Therapeutics completes a phase I trial in COVID-2019 infections in USA (Intranasal) (NCT06063330)
- 02 Oct 2023 Early research in Common cold in USA prior to October 2023 (Intranasal) (Red Queen Therapeutics pipeline, October 2023)